[HTML][HTML] Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis

PL McCarthy, SA Holstein, MT Petrucci… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
PL McCarthy, SA Holstein, MT Petrucci, PG Richardson, C Hulin, P Tosi, S Bringhen…
Journal of Clinical Oncology, 2017ncbi.nlm.nih.gov
Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation
(ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or
observation in several randomized controlled trials (RCTs) of patients with newly diagnosed
multiple myeloma (NDMM). All studies had PFS as the primary end point, and none were
powered for overall survival (OS) as a primary end point. Thus, a meta-analysis was
conducted to better understand the impact of lenalidomide maintenance in this setting.
Abstract
Purpose
Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or observation in several randomized controlled trials (RCTs) of patients with newly diagnosed multiple myeloma (NDMM). All studies had PFS as the primary end point, and none were powered for overall survival (OS) as a primary end point. Thus, a meta-analysis was conducted to better understand the impact of lenalidomide maintenance in this setting.
ncbi.nlm.nih.gov